Search Filters

Search Results

Found 1 results

510(k) Data Aggregation

    K Number
    K960706
    Manufacturer
    Date Cleared
    1996-04-25

    (64 days)

    Product Code
    Regulation Number
    870.3450
    Reference & Predicate Devices
    Why did this record match?
    Device Name :

    VASCUTEK VASCUSOFT PLUS VASCULAR GRAFT

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The Vascusoft™ Plus Vascular Graft is indicated for systemic vascular repair, i.e. replacement or bypass in aneurysmal and occlusive disease of arteries. Coronary vascular repair and blood access fistula (e.g. hemodialysis) are contraindicated with this device.

    Device Description

    The Vascusoft™ Plus Vascular Graft is a warp knitted polyester prosthesis with a porosity of 2591 ml/min/cm² which is available in a straight tube and bifurcated configurations.

    AI/ML Overview

    This document is a 510(k) summary for a medical device (VASCUTEK VASCUSOFT™ PLUS VASCULAR GRAFT), not a study report describing the acceptance criteria and performance of an AI/ML powered device. Due to this, the questions you've asked about AI/ML device performance, such as sample sizes for test sets, expert ground truth, MRMC studies, standalone performance, and training set details, are not applicable here.

    However, I can extract the non-AI-specific acceptance criteria and general performance claims from the provided text as best as possible, interpreting your request in the context of this document.

    Acceptance Criteria and Reported Device Performance (Non-AI Context)

    Acceptance Criteria CategorySpecific Criteria/TestsDevice Performance (Vascusoft™ Plus)Comparison Device (Vascusoft™)
    Material EquivalenceMaterial compositionPolyesterPolyester
    Intended Use EquivalenceIndication for useSystemic vascular repair, replacement/bypass for aneurysmal and occlusive disease of arteries.Systemic vascular repair, replacement/bypass for aneurysmal and occlusive disease of arteries.
    Function EquivalenceGeneral function (graft performance)Safe & EffectiveSafe & Effective
    Physical PropertiesPorosity2591 ml/min/cm²Not explicitly stated for Vascusoft™ in document
    In-vitro PerformanceBurst StrengthPerformed acceptablyPerformed acceptably
    Suture RetentionPerformed acceptablyPerformed acceptably
    Tensile StrengthPerformed acceptablyPerformed acceptably
    Water PermeabilityPerformed acceptablyPerformed acceptably
    Resistance to DilatationEnhanced resistance (in-vitro studies)Implied to be less resistant than 'Plus' version
    BiocompatibilityBiocompatibilityThoroughly tested & characterized, suitable for intended use.Thoroughly tested & characterized, suitable for intended use.
    SterilizationMethod of SterilizationEthylene OxideNot explicitly stated for Vascusoft™ in document
    Shelf-lifeShelf-life5 yearsNot explicitly stated for Vascusoft™ in document
    In-vivo PerformanceAnimal EvaluationsAcceptable for intended purpose.Not explicitly stated for Vascusoft™ in document

    Responses to Specific Questions in the Context of this Document:

    1. A table of acceptance criteria and the reported device performance: See the table above. The "acceptance criteria" here are interpreted as the aspects that needed to be demonstrated for substantial equivalence or safety/effectiveness. The "reported device performance" reflects what the document states about the Vascusoft™ Plus.

    2. Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective):

      • Sample Size: Not specified for any of the in-vitro or animal tests. The document only states "Comprehensive performance testing has been performed" and "Animal testing has demonstrated acceptable in-vivo performance."
      • Data Provenance: Not specified. It's a regulatory submission, so likely company-sponsored internal testing, but the country of origin or whether it's retrospective/prospective isn't mentioned.
    3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience): Not applicable. This document describes physical and biological testing of a vascular graft, not expert review of AI output.

    4. Adjudication method (e.g. 2+1, 3+1, none) for the test set: Not applicable. This is for AI model output adjudication, not physical device testing.

    5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance: Not applicable. This is a traditional medical device, not an AI-powered one.

    6. If a standalone (i.e. algorithm only without human-in-the loop performance) was done: Not applicable.

    7. The type of ground truth used (expert concensus, pathology, outcomes data, etc): For the physical and biological testing, the "ground truth" would be established by standardized measurement methods (e.g., using calibrated equipment for burst strength, standardized assays for biocompatibility) and observable biological responses in animal models. It's not a "ground truth" in the AI sense.

    8. The sample size for the training set: Not applicable. This device does not have a "training set."

    9. How the ground truth for the training set was established: Not applicable.

    In summary, this document is a regulatory submission for a non-AI medical device. The concepts of acceptance criteria for AI performance, expert adjudication, training/test sets, and ground truth for AI models are not relevant to its content.

    Ask a Question

    Ask a specific question about this device

    Page 1 of 1